BriaCell Therapeutics Corp. · NASDAQ (us_market)
Healthcare · Biotechnology · Canada
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-13$10.92 RISE2026-05-15$3.02 PEAK2026-05-20$3.88 127d | -72.3% 122d | Missed | Missed | — | — | +28.5% 5d | Missed |
DROP2025-10-24$13.79 RISE2026-02-24$3.67 PEAK2026-04-15$4.62 173d | -73.4% 123d | Missed | Missed | — | — | +25.9% 50d | Missed |
DROP2025-10-24$13.79 RISE2025-11-20$7.02 PEAK2025-12-03$12.64 40d | -49.1% 27d | Missed | Missed | — | — | +80.1% 13d | Missed |
DROP2025-04-24$60.30 RISE2025-08-06$6.30 PEAK2025-10-24$13.79 183d | -89.6% 104d | Missed | Missed | — | — | +118.9% 79d | Missed |
DROP2025-04-24$60.30 RISE2025-05-15$29.20 PEAK2025-05-20$35.60 26d | -51.6% 21d | Missed | Missed | — | — | +21.9% 5d | Missed |
DROP2025-01-29$59.00 RISE2025-03-04$31.80 PEAK2025-04-24$60.30 85d | -46.1% 34d | Missed | Missed | — | — | +89.6% 51d | Missed |
DROP2024-09-30$12.40 RISE2025-01-28$3.70 PEAK2025-04-24$60.30 206d | -70.2% 120d | Missed | Missed | — | — | +1529.7% 86d | Missed |
DROP2024-09-30$12.40 RISE2024-11-19$5.70 PEAK2025-01-29$59.00 121d | -54.0% 50d | Missed | Missed | — | — | +935.1% 71d | Missed |
DROP2024-05-09$22.60 RISE2024-09-17$4.70 PEAK2024-09-30$12.40 144d | -79.2% 131d | Missed | Missed | — | — | +163.8% 13d | Missed |
DROP2024-04-08$29.30 RISE2024-08-14$5.50 PEAK2024-09-30$12.40 175d | -81.2% 128d | Missed | Missed | — | — | +125.5% 47d | Missed |
DROP2023-08-25$75.30 RISE2023-12-19$39.40 PEAK2023-12-29$58.50 126d | -47.7% 116d | Missed | Missed | — | — | +48.5% 10d | Missed |
DROP2023-08-25$75.30 RISE2023-10-27$37.90 PEAK2023-12-29$58.50 126d | -49.7% 63d | Missed | Missed | — | — | +54.4% 63d | Missed |
DROP2023-04-17$75.80 RISE2023-07-27$60.00 PEAK2023-08-25$75.30 130d | -20.8% 101d | Missed | Missed | — | — | +25.5% 29d | Missed |
DROP2023-02-15$79.90 RISE2023-06-21$57.20 PEAK2023-08-25$75.30 191d | -28.4% 126d | Missed | Missed | — | — | +31.6% 65d | Missed |
DROP2023-02-15$79.90 RISE2023-03-10$61.20 PEAK2023-04-17$75.80 61d | -23.4% 23d | Missed | Missed | — | — | +23.9% 38d | Missed |
1–15 / 36 1 / 3 | |||||||
No scored news yet for a sentiment trend.
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer, is designed with
BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed
Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal
BriaCell Therapeutics (BCT.TO) has received FDA approval to initiate clinical evaluation of its next
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity across multiple
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new
TryHard (THH) unveiled on Wednesday an equity purchase agreement in which Summer Explorer Investment
US equity futures were down ahead of Wednesday's opening bell as traders digested more bank earnings
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCTX | -12.92% | -9.45% | -48.80% | -89.42% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.89% | -3.74% | -45.36% | -102.11% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-10-15 | -12.11 | 0.04 | +100.37% |
| 2025-06-16 | -17.60 | -16.40 | +6.82% |
| 2025-03-12 | -19.40 | -23.30 | -20.10% |
| 2024-12-16 | -12.00 | -33.00 | -175.00% |
| 2024-10-28 | -78.00 | -10.50 | +86.54% |
| 2024-06-14 | -82.50 | 16.50 | +120.00% |
| 2024-03-18 | -30.00 | -106.50 | -255.00% |
| 2023-12-14 | -27.00 | 54.00 | +300.00% |
| 2023-10-25 | -59.25 | -21.00 | +64.56% |
| 2023-06-14 | -53.25 | -48.00 | +9.86% |
| 2023-03-15 | -53.25 | -115.50 | -116.90% |
| 2022-12-14 | -49.50 | -10.50 | +78.79% |
| 2022-10-27 | -45.75 | -153.00 | -234.43% |
| 2022-06-13 | -31.50 | -48.00 | -52.38% |
| 2022-03-14 | -24.75 | -36.00 | -45.45% |